Financial Performance - The company reported a revenue of HKD 12,912 thousand for the three months ended June 30, 2023, representing a 23.3% increase from HKD 10,467 thousand in the same period of 2022[4] - The loss before tax for the period was HKD 550 thousand, compared to a loss of HKD 799 thousand in the previous year, indicating a 30.9% improvement[4] - The basic and diluted loss per share was HKD 0.14, an improvement from HKD 0.20 in the same quarter of the previous year[4] - The total comprehensive loss for the period was HKD 530 thousand, compared to HKD 792 thousand in the previous year, showing a 33.0% reduction[6] - The company reported a loss attributable to owners of the company of HKD 539 million for the three months ended June 30, 2023, compared to a loss of HKD 786 million for the same period in 2022, representing a 31.5% improvement[26] - The loss attributable to the company's owners for the three months ended June 30, 2023, was HKD 0.5 million, a decrease of HKD 0.3 million or 31.4% from HKD 0.8 million for the same period in 2022[57] - Basic loss per share for the period was HKD 0.14, down 30.0% from HKD 0.20 in the previous year[57] Revenue Breakdown - The revenue from medical consultation services was HKD 303 thousand, up from HKD 225 thousand, reflecting a 34.7% increase year-over-year[9] - The revenue from prescription and dispensing services increased to HKD 2,489 thousand from HKD 2,077 thousand, marking a 19.9% growth[9] - The revenue from treatment services rose to HKD 10,120 thousand, compared to HKD 8,165 thousand, which is a 24.0% increase[9] - Advisory service revenue increased to HKD 167,000 for the three months ended June 30, 2023, up from HKD 51,000 in the same period of 2022, marking a significant increase of 227.5%[22] - The revenue breakdown includes HKD 0.3 million from medical diagnosis services, HKD 2.5 million from prescription and dispensing services, and HKD 10.1 million from treatment services, accounting for 2.3%, 19.3%, and 78.4% of total revenue respectively[60] Operational Insights - The company operates primarily in Hong Kong, with nearly all revenue generated from external customers located there[20] - The company is focused on expanding its services in medical consultation, prescription and dispensing, and treatment services[19] - The company plans to continue market research and evaluation of new products, skills, and treatment technologies to drive business growth and maintain competitiveness[45] - The company maintains a cautious optimism regarding future performance, anticipating a recovery in local consumer sentiment and sales due to the lifting of COVID-19 restrictions and the resumption of cross-border travel with mainland China[58] - The company aims to strengthen its market position and identify new business opportunities to enhance brand development and maximize returns for investors[58] Cost and Expenses - Employee costs rose by HKD 1.4 million or 28.3% to HKD 6.3 million for the three months ended June 30, 2023, primarily due to increased revenue leading to higher salaries and performance bonuses for doctors[47] - Other income, losses, and expenses increased to a net loss of HKD 167,000, up HKD 124,000 or 288.4% from HKD 43,000 in the previous year, primarily due to the absence of government subsidies[61] - Other expenses rose by HKD 0.2 million or 12.0% to HKD 2.0 million, consistent with the increase in revenue[65] - For the three months ended June 30, 2023, the group's cost of used inventory was HKD 2.4 million, compared to HKD 2.0 million for the same period in 2022, representing 18.7% of revenue for both periods[89] Corporate Governance - The company has adopted a share option scheme to reward and/or return contributions from eligible individuals, compliant with GEM Listing Rules Chapter 23[84] - As of June 30, 2023, there were no unexercised share options under the share option scheme[85] - The company is committed to appointing sufficient independent non-executive directors to comply with GEM Listing Rules within three months from June 7, 2023[82] - The board of directors includes both executive and independent non-executive members, ensuring oversight and balance in decision-making processes[87] - The company has acknowledged the need to maintain a positive relationship between executive and non-executive directors to enhance operational efficiency[81] - The board will regularly meet to discuss significant matters affecting the group's operations[81] - The company has confirmed compliance with applicable laws and sufficient disclosures have been made[88] Tax and Liabilities - The company did not incur any tax provisions for Hong Kong profits tax during the periods as there were no estimated taxable profits[66] - The company has a net current liability of HKD 3.0 million as of June 30, 2023, primarily due to contract liabilities of HKD 19.3 million, which are expected to be fulfilled without cash outflow[32] Market Presence - The company operates two "Medicskin" brand medical skin care centers in prime locations in Hong Kong, focusing on treating skin diseases and improving customer appearance[42] - The company has not reported any significant impact from the new Hong Kong Financial Reporting Standards that came into effect on April 1, 2023[7] - The company has no major customers contributing more than 10% of total revenue for the three months ended June 30, 2023, and 2022, indicating a diversified customer base[33]
密迪斯肌(08307) - 2024 Q1 - 季度财报